Nilemdo 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0023 
C.I.z - Changes (Safety/Efficacy) of Human and 
01/04/2022 
PL 
To update the contact details of the local 
Veterinary Medicinal Products - Other variation 
representatives in CZ and SK.  
In addition the MAH has taken the opportunity to 
align the ES SmPC section 4.1 to the approved 
EN annexes 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
IB/0022 
B.II.b.3.z - Change in the manufacturing process of 
11/03/2022 
n/a 
the finished or intermediate product - Other variation 
PSUSA/10841
Periodic Safety Update EU Single assessment - 
10/03/2022 
n/a 
PRAC Recommendation - maintenance 
/202108 
bempedoic acid, bempedoic acid / ezetimibe 
WS/2177/G 
This was an application for a group of variations 
13/01/2022 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.1.g - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Introduction of a new manufacturer of the AS that is 
not supported by an ASMF and requires significant 
update to the relevant AS section in the dossier 
IB/0021/G 
This was an application for a group of variations. 
11/01/2022 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.e.5.a - Implementation of changes foreseen in an 
approved change management protocol - Requires 
no further supportive data 
B.I.e.5.a - Implementation of changes foreseen in an 
approved change management protocol - Requires 
Page 2/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
no further supportive data 
B.I.e.5.a - Implementation of changes foreseen in an 
approved change management protocol - Requires 
no further supportive data 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
IB/0020 
C.I.11.z - Introduction of, or change(s) to, the 
04/01/2022 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0016 
C.I.z - Changes (Safety/Efficacy) of Human and 
17/10/2021 
SmPC 
Veterinary Medicinal Products - Other variation 
PSUSA/10841
Periodic Safety Update EU Single assessment - 
30/09/2021 
n/a 
PRAC Recommendation - maintenance 
/202102 
bempedoic acid, bempedoic acid / ezetimibe 
IB/0017/G 
This was an application for a group of variations. 
25/08/2021 
n/a 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
Page 3/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.4.c - Change to in-process tests or limits 
applied during the manufacture of the AS - Deletion 
of a non-significant in-process test 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
WS/2083/G 
This was an application for a group of variations 
08/07/2021 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
C.I.13 - Other variations not specifically covered 
Page 4/8 
 
 
 
 
 
 
 
 
 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
IAIN/0015/G 
This was an application for a group of variations. 
02/06/2021 
05/07/2021 
Annex II and 
PL 
B.I.e.5.a - Implementation of changes foreseen in an 
approved change management protocol - Requires 
no further supportive data 
A.7 - Administrative change - Deletion of 
manufacturing sites 
II/0007 
C.I.13 - Other variations not specifically covered 
15/04/2021 
n/a 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
PSUSA/10841
Periodic Safety Update EU Single assessment - 
11/03/2021 
n/a 
PRAC Recommendation - maintenance 
/202008 
bempedoic acid, bempedoic acid / ezetimibe 
IB/0011 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
22/12/2020 
05/07/2021 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
Page 5/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0012/G 
This was an application for a group of variations. 
17/12/2020 
n/a 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
IB/0010 
B.II.b.3.z - Change in the manufacturing process of 
11/12/2020 
n/a 
the finished or intermediate product - Other variation 
IB/0009 
C.I.z - Changes (Safety/Efficacy) of Human and 
10/12/2020 
05/07/2021 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
IB/0006/G 
This was an application for a group of variations. 
22/10/2020 
n/a 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IB/0005/G 
This was an application for a group of variations. 
30/07/2020 
n/a 
B.I.b.1.h - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition or 
Page 6/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
replacement (excl. Biol. or immunol. substance) of a 
specification parameter as a result of a safety or 
quality issue 
B.I.b.1.h - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition or 
replacement (excl. Biol. or immunol. substance) of a 
specification parameter as a result of a safety or 
quality issue 
IAIN/0004/G 
This was an application for a group of variations. 
17/07/2020 
05/07/2021 
SmPC, 
Labelling and 
PL 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
Page 7/8 
 
 
 
 
 
 
 
 
the range of the currently approved pack sizes 
II/0002 
C.I.13 - Other variations not specifically covered 
09/07/2020 
n/a 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
T/0001 
Transfer of Marketing Authorisation 
07/05/2020 
12/06/2020 
SmPC, 
Labelling and 
PL 
IB/0003 
B.II.b.3.z - Change in the manufacturing process of 
05/06/2020 
n/a 
the finished or intermediate product - Other variation 
Page 8/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
